Novartis stock faces Q3 earnings squeeze after profit slump
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis just dropped its Q3 2026 numbers and the headline is simple. Earnings power looks squeezed while the share price into the release had been grinding higher, with a 30‑day gain of about 7.5% and a flat 90‑day track. That is a sentiment clash. The market has been paying a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishShrinking net margin against a high multiple can weigh on a large pharma stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The trailing net margin fell to 17.5% from 25.5%.
- 02The cited P/E is 29.5x.
- 03Q3 2026 revenue was US$15,029m versus US$14,358m a year earlier.